Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Glenmark Pharmaceuticals Limited    GLENMARK   INE935A01035

GLENMARK PHARMACEUTICALS LIMITED

(GLENMARK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
01/20/2020 01/21/2020 01/22/2020 01/23/2020 01/24/2020 Date
350.7(c) 351(c) 350.05(c) 350.9(c) 350.75 Last
2 652 645 1 313 180 1 520 164 777 768 1 121 453 Volume
-2.57% +0.09% -0.27% +0.24% -0.04% Change
More quotes
Financials (INR)
Sales 2020 106 B
EBIT 2020 12 885 M
Net income 2020 7 331 M
Debt 2020 34 005 M
Yield 2020 0,61%
Sales 2021 118 B
EBIT 2021 14 849 M
Net income 2021 9 000 M
Debt 2021 32 536 M
Yield 2021 0,65%
P/E ratio 2020 13,5x
P/E ratio 2021 10,9x
EV / Sales2020 1,25x
EV / Sales2021 1,12x
Capitalization 98 970 M
More Financials
Company
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven... 
Sector
Pharmaceuticals
Calendar
02/11Earnings Release
More about the company
Surperformance© ratings of Glenmark Pharmaceuticals L
Trading Rating : Investor Rating :
More Ratings
Latest news on GLENMARK PHARMACEUTICALS L
2019BAUSCH HEALTH : Announces Resolution Of BRYHALI Lotion, 0.01%, Intellectual Prop..
AQ
2019GLENMARK PHARMACEUTICALS : announces product approval for Ryaltris in Australia
AQ
2019GLENMARK PHARMACEUTICALS : Certificate of Compliance issued by the European regu..
AQ
2019GLENMARK PHARMACEUTICALS : receives approval from Russian Ministry of Healthcare..
AQ
2019GLENMARK PHARMACEUTICALS : secures its position in the prestigious Dow Jones Sus..
AQ
2019GLENMARK PHARMACEUTICALS LTD : Ex-dividend day for final dividend
FA
2019GLENMARK PHARMACEUTICALS : Receives Orphan Drug Designation for GBR 1342, a Bisp..
AQ
2019GLENMARK PHARMACEUTICALS : receives approval for combination of Remogliflozin Et..
AQ
2019GLENMARK PHARMACEUTICALS : Fitch Affirms Glenmark Pharmaceuticals at 'BB' Outloo..
AQ
2019GLENMARK PHARMACEUTICALS : to partner with Novartis to promote, commercialize an..
AQ
2019GLENMARK PHARMACEUTICALS : signs deal with Novartis over distribution in Brazil
AQ
2019GLENMARK PHARMACEUTICALS : Novartis Partner to Distribute COPD Products in Brazi..
DJ
2019GLENMARK PHARMACEUTICALS : Pharma says USFDA has issued CRL for Ryaltris
AQ
2019GLENMARK PHARMACEUTICALS : consolidated revenue rises 12.44% to Rs. 25,634.74 Mn..
AQ
2019GLENMARK PHARMACEUTICALS LTD : annual earnings release
More news
News in other languages on GLENMARK PHARMACEUTICALS L
2019GLENMARK PHARMACEUTICALS LTD : Ex-dividend day for final dividend
2019GLENMARK PHARMACEUTICALS LTD : Veröffentlichung des Jahresergebnisses
2019GLENMARK PHARMACEUTICALS LTD : publication des résultats annuels
2018Nesselsucht-Medikament von Roche droht neue Konkurrenz
2018GLENMARK PHARMACEUTICALS LTD : Ex-dividend day for final dividend
More news
Analyst Recommendations on GLENMARK PHARMACEUTICALS L
More recommendations
Sector news : Generic Pharmaceuticals
02:48aCREDIT MARKETS : New Bond Sales Set Fast Pace In January -- WSJ
DJ
01/24BAYER : Latest Roundup Weedkiller Trial Postponed Amid Settlement Talks--Update
DJ
01/24BAYER : Latest Roundup Weedkiller Trial Postponed Amid Settlement Talks
DJ
01/24Bayer Roundup cancer trial postponed to continue settlement talks
RE
01/24Hunt For Yield Boosts Corporate Bond Sales and Prices
DJ
More sector news : Generic Pharmaceuticals
Chart GLENMARK PHARMACEUTICALS LIMITED
Duration : Period :
Glenmark Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLENMARK PHARMACEUTICALS L
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 432,68  INR
Last Close Price 350,75  INR
Spread / Highest target 89,0%
Spread / Average Target 23,4%
Spread / Lowest Target -8,77%
EPS Revisions
Managers
NameTitle
Glenn Mario Saldanha Chairman, Chief Executive Officer & MD
Kurt Stoeckli Co-President & Chief Scientific Officer
Jayaram Philkana Co-President & Chief Human Resources Officer
Mahboob Rahman Co-President & Chief Medical Officer
V. S. Mani Chief Financial Officer & Executive Director